An efficacy and safety study of Telaprevir in patients with genotype 1 Hepatitis C infection after liver transplantation

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-004724-35

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

to determine the efficacy of telaprevir administered as 750 mg every 8 hours (q8h) in combination with pegylated interferon (Peg-IFN)-alfa-2a and ribavirin (RBV) in genotype 1 chronic HCV infected liver transplant patients as measured by sustained virologic response (SVR12planned). SVR12planned is defined as having HCV ribonucleic <25 IU/mL acid (RNA) level 12 weeks after the last planned dose of study medication.


Critère d'inclusion

  • Chronic Hepatitis C Infection